Algert Global LLC Invests $288,000 in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Algert Global LLC invested $288,000 in Regeneron Pharmaceuticals by purchasing 454 shares, according to their recent SEC filing.
• Regeneron Pharmaceuticals has received mixed ratings from analysts, with target prices ranging from $580.00 to $850.00, and a consensus rating of "Moderate Buy."
• The company recently announced a quarterly dividend of $0.88 per share, representing an annualized yield of 0.6%.

Algert Global LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 454 shares of the biopharmaceutical company's stock, valued at approximately $288,000.

A number of other hedge funds have also recently made changes to their positions in REGN. Brighton Jones LLC grew its holdings in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after acquiring an additional 686 shares in the last quarter. American Assets Inc. purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $427,000. Integrated Wealth Concepts LLC increased its position in Regeneron Pharmaceuticals by 55.5% during the 4th quarter. Integrated Wealth Concepts LLC now owns 1,163 shares of the biopharmaceutical company's stock valued at $828,000 after purchasing an additional 415 shares during the period. Kovitz Investment Group Partners LLC increased its position in Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 3,839 shares of the biopharmaceutical company's stock valued at $2,735,000 after purchasing an additional 148 shares during the period. Finally, Capital Analysts LLC increased its position in Regeneron Pharmaceuticals by 21.0% during the 4th quarter. Capital Analysts LLC now owns 397 shares of the biopharmaceutical company's stock valued at $283,000 after purchasing an additional 69 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on REGN. Canaccord Genuity Group reissued a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Citigroup reissued a "buy" rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Finally, Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price on the stock. in a research report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $829.65.

Regeneron Pharmaceuticals Stock Down 2.9%

Shares of Regeneron Pharmaceuticals stock opened at $572.38 on Tuesday. The firm's 50 day moving average price is $551.47 and its 200-day moving average price is $589.46. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20. The company has a market cap of $60.67 billion, a P/E ratio of 14.42, a PEG ratio of 1.96 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3,675,600 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the previous year, the firm earned $11.56 EPS. The company's quarterly revenue was up 3.6% compared to the same quarter last year. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be paid a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.